Top 50 Clinical Trial Platform - Late Stage

Pi Health provides an AI-native clinical trial platform that unifies fragmented systems into a single intelligent source of truth. This platform integrates AI validation and operational workflows across EDC, CTMS, and eTMF functions to eliminate manual reconciliation. The result is faster study startup, reduced queries, and quicker database lock for clinical development.

Paradigm is developing a platform that integrates clinical trial management systems to enhance trial efficiency and reduce participation barriers for both patients and healthcare providers. By creating a unified infrastructure, Paradigm aims to provide equitable access to clinical trials, accelerating the delivery of potentially life-saving therapies.

Medable provides a digital platform for decentralized clinical trials that utilizes patient-generated data to enhance participant recruitment and streamline data collection. By integrating tools for remote scheduling, consent management, and real-time reporting, the platform improves the efficiency and quality of clinical research across over 60 countries.

The startup offers a remote patient research platform that integrates validated studies and connects with wearables and medical devices, facilitating seamless data transfer into existing systems. This technology enables biopharma and home health professionals to efficiently design and scale clinical research programs while ensuring compliance with data requirements.

The startup develops clinical data software that utilizes artificial intelligence and natural language processing to extract relevant clinical data points and create unified patient graphs from fragmented medical documents. This technology enables healthcare professionals to efficiently identify and match eligible patients to clinical trials, enhancing recruitment processes and improving trial outcomes.

N Power Medicine develops and commercializes novel therapeutics targeting neurological and psychiatric disorders. The company focuses on small molecule drug candidates designed to modulate specific receptor pathways implicated in disease pathology. Their pipeline aims to offer improved efficacy and tolerability profiles for patients with unmet medical needs.

ObvioHealth offers the ObvioGo® 2.0 platform, which utilizes digital tools for real-time data capture and participant engagement in clinical trials. This technology addresses inefficiencies in traditional trial management by providing customizable study designs and enhancing data accuracy, resulting in faster recruitment and improved compliance.

The startup operates an integrated research organization that embeds clinical trials at the point of care, collaborating with healthcare providers to enhance patient participation and streamline data collection. This approach reduces the drug development timeline, improving access to clinical trials and outcomes for healthcare organizations.

Lindus Health operates as an anti-CRO, utilizing a proprietary software platform and access to 30 million Electronic Health Records to execute end-to-end clinical trials with fixed pricing and milestone-based payments. By streamlining study design, patient recruitment, and data management, Lindus delivers trials up to three times faster than traditional CROs, ensuring timely access to new treatments for patients.

Teckro provides a data-driven platform that enhances site engagement in clinical trials through real-time analytics and targeted interventions. By quantifying site performance, Teckro improves recruitment rates and accelerates study timelines, delivering measurable outcomes for pharmaceutical and biotech sponsors.

Iterative Health accelerates gastrointestinal and hepatology clinical trials with an AI-powered platform and specialized services. The company optimizes clinical research sites to improve patient recruitment and site activation, reducing trial timelines.

The startup has developed a biotech platform that integrates a network of clinical trial sites within existing medical practices, utilizing a mobile cohort of certified research coordinators and advanced software to enhance participant recruitment for research studies. This approach increases access to diverse human subjects for clinical trials, psychological research, and focus groups, addressing the challenge of limited participant availability in traditional drug development processes.

OneStudyTeam offers a cloud‑based collaboration platform that centralizes clinical trial workflows for sponsors, CROs, sites, patients, and regulators. The solution provides real‑time enrollment dashboards, integrated pre‑screening linked to EHRs, and bi‑directional APIs with CTMS and eTMF systems, while maintaining GCP, HIPAA, and 21 CFR Part 11 compliance. Predictive analytics and modular plug‑ins help accelerate recruitment and reduce manual data handling.

Curebase provides decentralized clinical research software that enables efficient data collection through electronic patient-reported outcomes (ePRO) and electronic consent (eConsent) systems. The platform enhances participant engagement and accelerates study launches while ensuring high-quality data capture across diverse clinical trials.

ConcertAI is an AI-driven platform that utilizes real-world data and advanced analytics to enhance clinical trial design and execution in oncology. The company addresses the inefficiencies in cancer research by providing biopharma partners with actionable insights to accelerate drug development and improve patient outcomes.

H1 provides a health data platform that utilizes AI-enabled analytics to connect life sciences companies with healthcare professionals, enhancing clinical trial design and patient access. The platform addresses the challenge of identifying suitable investigators and optimizing diversity in clinical trials by delivering precise data insights and performance metrics.

Unlearn.ai develops machine-learning models that create digital twins of clinical trial participants, enabling the use of synthetic patient data to enhance control groups. This technology accelerates clinical trials by allowing smaller study designs while maintaining statistical power, ultimately reducing the time and cost associated with bringing new therapies to market.

Science 37 operates an FDA‑inspected direct‑to‑patient clinical trial site that enables sponsors to conduct all study visits, assessments, and data capture in participants’ homes through a network of certified research nurses. The platform integrates with sponsor eCRF systems, provides real‑time source‑verified data, and expands recruitment nationwide to improve patient diversity and accelerate enrollment timelines. It supports therapeutic‑area agnostic protocols while maintaining GCP compliance and remote monitoring.

Lightship utilizes inclusive technology and flexible visit options to enhance patient participation in clinical trials, removing geographic barriers and providing personalized support throughout the research process. This approach addresses the limited access and choice often faced by patients and providers, accelerating the development of new therapies for diverse populations.

Formation Bio offers an AI‑native platform that acquires clinical‑stage drug assets and accelerates their development through machine‑learning‑driven candidate scoring, automated trial design, and real‑time risk analytics. The cloud‑based solution integrates multi‑omics data, regulatory intelligence and secure collaboration tools, enabling pharmaceutical, biotech and academic partners to shorten milestones while generating revenue via licensing, milestone payments and royalties.

Elligo Health Research utilizes its proprietary IntElligo® technology and EHR data to connect healthcare providers with clinical trials, facilitating access to diverse patient populations across over 600 sites. This approach addresses the challenge of limited patient recruitment in clinical research by streamlining trial management and enhancing site participation.

Zephyr AI utilizes an AI-enabled platform that integrates diverse healthcare and biological data to identify optimal patient-drug matches and enhance clinical trial efficiency. This approach addresses the challenges of patient stratification and drug development costs, ultimately improving patient outcomes through personalized therapies.

XaiRec provides a platform for building and deploying explainable AI recommendation systems. It focuses on transparency by offering tools to understand model predictions and feature importance in real-time. This allows businesses to deploy trustworthy, auditable personalization engines across various customer touchpoints.

H1 offers an AI‑driven platform that consolidates global provider, site, patient, and health‑plan data into a searchable, continuously updated repository. The system ranks and matches physicians, sites, and patient cohorts to clinical trial, medical affairs, commercial, and network‑management use cases, delivering real‑time intelligence via web portals and APIs. This enables pharma, biotech, health‑plan operators, and digital‑health apps to streamline targeting, improve data accuracy, and accelerate decision‑making.

Humaneva provides clinical research data and insights to the medical community, enabling evidence-based decision-making and advancements in healthcare. They focus on delivering reliable data to support medical research and development.

This biotech startup utilizes a computational discovery engine to develop next-generation immunology nanobodies, enabling the creation of therapeutics with differentiated profiles at scale. By automating clinical trials, the company significantly reduces trial costs and enhances efficiency in drug development.

Healthcare organizations often work with fragmented, incomplete, or outdated provider and patient data, which hampers efficient site selection for clinical trials, slows patient recruitment, and limits precise HCP engagement for medical affairs and commercial activities. Health plans also struggle with inaccurate provider directories, leading to network inefficiencies and suboptimal patient access. H1 delivers an integrated platform that combines software applications and curated data feeds to provide a single source of truth for clinicians, researchers, commercial teams, and payers.

Immunai utilizes multi-omic single-cell analysis and machine learning to enhance drug development by optimizing clinical trials and evaluating preclinical assets. The company addresses the challenge of identifying effective treatment regimens and critical targets in human diseases, facilitating the advancement of immunomodulatory therapies.

Medbanks is a database platform that connects patients, healthcare providers, and pharmaceutical companies within the clinical oncology sector, facilitating access to essential medical services and information. The platform addresses the challenge of fragmented healthcare data by providing a centralized resource for clinical trials, treatment options, and professional medical services.

The startup develops clinically validated software applications that utilize artificial intelligence to analyze real-world data, enhancing patient outcomes and supporting the discovery of new medicines. By connecting patients, clinicians, and researchers, the platform generates extensive phenotypic databases that enable discovery research companies to maximize revenue in the healthcare sector.

Truveta aggregates de-identified EHR data, clinical notes, and images from numerous health systems to create a large, representative real-world data asset. This platform supports life science, public health, and healthcare organizations in safety monitoring, HEOR studies, and clinical trial optimization. The company provides powerful analytics, including a proprietary language model, to accelerate therapy adoption and improve care quality.

The startup develops cancer medicines and treatments that expedite the clinical trial process, enabling faster access to therapies for patients. By streamlining drug development, the company increases the availability of effective cancer treatments, addressing the urgent need for timely interventions in oncology.

The company provides an integrated laboratory platform that combines nonclinical toxicology, pharmacology, ADME studies and clinical bioanalysis, biomarker, genomics, and companion‑diagnostic testing. Its cloud‑based, FHIR‑compatible data hub aggregates assay results, real‑world evidence and AI‑driven analytics to generate regulatory‑ready reports, while a global logistics network and regulatory consulting enable pharmaceutical and biotech firms to manage samples and submissions through a single contract.

Tasso supplies FDA‑cleared, at‑home blood collection devices that obtain 200‑600 µL of capillary whole blood or dried‑blood spots via a painless, vacuum‑driven lancet, compatible with standard microtainer tubes or proprietary cartridges. The company also provides an end‑to‑end logistics and data platform (Tasso Connect) with prepaid shipping, remote proctoring, and a secure API/dashboard for real‑time sample tracking and integration with laboratory or EHR systems, supporting decentralized clinical trials and remote monitoring.

Happy Ring develops a wearable medical device that utilizes proprietary biometric sensors and generative AI to continuously monitor brain and body biomarkers, providing real-time health insights. This technology enhances patient outcomes by delivering accurate, clinical-grade data for remote patient monitoring and clinical trials, reducing recruitment times and improving treatment precision.

The startup is developing a Clinical Digital Twin Platform that creates virtual replicas of patients using real-time health data and advanced modeling techniques. This platform enables healthcare providers to personalize treatment plans and improve patient outcomes by simulating various clinical scenarios.

The startup provides genomic medicine delivery by connecting individuals and healthcare providers with genetic experts for personalized genetic assessments and clinical action plans. This approach enables patients to make informed treatment decisions while facilitating faster disease diagnosis for medical practitioners at reduced costs.

The startup offers a cloud-based research data management platform that automates workflows for biomedical research, enabling collaborative studies and machine learning applications. This platform enhances data scalability and analysis, facilitating multicenter clinical trials and accelerating the pace of scientific discoveries.

Owkin utilizes AI and multimodal patient data to identify biomarkers and match patient subpopulations with targeted drug candidates, enhancing the precision of drug discovery and development. This approach accelerates clinical trials and improves diagnostic accuracy, ultimately aiming to deliver the right treatment to each patient.

Mendel is an AI platform that combines large language models with a clinical hypergraph to enable physician-level cognitive reasoning for analyzing structured and unstructured clinical data. It enhances clinical data workflows by providing accurate cohort retrieval and chart review, ensuring outputs are explainable and grounded in a coherent patient journey.

Nucleai has developed an AI-powered platform that utilizes military-grade geospatial analysis to interpret complex cellular interactions in biopsy samples, generating spatial biomarkers for precision medicine. This technology enhances drug development by providing actionable insights that improve patient selection for clinical trials and optimize treatment strategies.

Noetik develops frontier AI models trained on extensive multimodal tumor data to predict individual patient responses to cancer treatments. This platform enhances clinical trial enrichment by accurately identifying likely responders for specific therapies. The technology aims to improve drug positioning and accelerate the discovery of novel, human-relevant oncology targets.

Kardigan develops novel therapeutics focused on addressing major cardiovascular diseases like genetic dilated cardiomyopathy and calcific aortic valve stenosis. The company utilizes its "Cardiac Intelligence" platform to modernize the discovery and development of targeted treatments for heart conditions. Their pipeline aims to create medical interventions for conditions that currently carry significant morbidity and mortality risks.

The company operates an end‑to‑end biopharmaceutical platform that discovers targets, conducts Phase 1‑3 trials, and manufactures biologics, small‑molecule drugs, and vaccines under GMP standards. It aggregates trial and real‑world data in a cloud‑based hub to support regulatory submissions, pharmacovigilance, and outcome analytics, and provides FHIR‑compatible APIs for EHR integration and electronic prescribing. A patient assistance portal offers insurance navigation, co‑pay support, and free medication for eligible patients, improving access for providers and patients treating chronic and acute diseases.

Aignostics develops AI foundation models for precision medicine, specializing in processing complex biomedical and digital pathology data. The company offers products for tumor microenvironment profiling and services for target discovery and translational research. Their platform enables the development of validated digital diagnostic tools to improve drug development and patient outcomes.

Lantern Pharma develops precision oncology therapies using artificial intelligence, machine learning, and genomics to enhance the efficiency and accuracy of drug discovery and development. The company addresses the high costs and lengthy timelines associated with oncology drug development by utilizing a data-driven platform that analyzes over 100 billion data points to identify effective treatment candidates.

Pathos develops an AI-enabled drug discovery platform that utilizes real-world oncology data and patient-derived functional genomic data to enhance patient selection and biomarker development. The platform aims to expedite the drug development process for biopharmaceutical companies by identifying promising therapeutic candidates that address significant unmet medical needs.

Biofourmis develops a technology platform that utilizes remote patient monitoring and AI-driven analytics to facilitate in-home healthcare, enabling patients to receive inpatient-level care at home. This approach addresses hospital capacity issues and reduces readmission rates by providing continuous care and timely interventions for chronic conditions.

Patients with chronic lung diseases often lack access to safe, clinically validated technologies that can monitor disease progression and deliver targeted therapies, leading to delayed interventions and reduced quality of life. Existing respiratory care solutions are frequently limited to hospital settings, cumbersome to use, and do not integrate real‑time data analytics for personalized treatment decisions. Apreo Health is developing investigational medical devices that combine advanced pulmonary sensing, drug delivery, and cloud‑based analytics to address gaps in respiratory care.

The company develops oral, enzyme‑targeted small‑molecule therapies that enhance glycolytic flux in red blood cells to increase ATP production and reduce hemolysis in rare hemolytic anemias such as pyruvate kinase deficiency, thalassemia, and sickle cell disease. Its platform combines structure‑based drug design, biomarker‑driven adaptive trials, and companion diagnostics to deliver disease‑modifying effects and support precision enrollment for hematologists and specialty clinics. Partnerships with pharmaceutical firms and academic centers accelerate development and broaden access to these metabolic treatments.